Skip to main content
SpringerLink
Log in

Wie muss die Therapie angepasst werden?

Antikoagulation des adipösen Patienten

  • Fortbildung
  • Adipositas
  • Published:
CardioVasc Aims and scope

An Erratum to this article was published on 30 October 2017

Standarddosierungen von Heparinen und Fondaparinux sollten unter Beachtung substanzspezifischer Strategien erhöht werden. Regelmäßige INR-Kontrollen von Phenprocoumon/Warfarin machen spezifische Dosisempfehlungen unnötig. Für DOAK liegen Daten nur bei moderat adipösen Patienten vor, eine Dosisanpassung erscheint hier nicht notwendig. Der Einsatz der DOAK im Rahmen malabsorptiver chirurgischer Eingriffe wird derzeit nicht empfohlen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost. 2007;5:937–41

    Article  CAS  PubMed  Google Scholar 

  2. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011;155:137–49

    Article  CAS  PubMed  Google Scholar 

  3. Raschke RA, Reilly BM, Guidry JR et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. 1993;119:874–81

    Article  CAS  PubMed  Google Scholar 

  4. Isherwood M, Murphy ML, Bingham AL et al. Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients. J Thromb Thrombolysis. 2017 Jan 9. doi: 10.1007/s11239-016-1466-9

    Google Scholar 

  5. Myzienski AE, Lutz MF, Smythe MA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy. 2010;30:324

    Article  PubMed  Google Scholar 

  6. Rowan BO, Kuhl DA, Lee MD et al. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008;18:162–6

    Article  PubMed  Google Scholar 

  7. Wang TF, Milligan PE, Wong CA et al. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88–93

    Article  CAS  PubMed  Google Scholar 

  8. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol. 2012;87:740–3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Spinler SA, Ou FS, Roe MT et al. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy. 2009;29:631–8

    Article  PubMed  Google Scholar 

  10. Walden A, Levison R, Singh S, Keeling D. A case of fatal pulmonary embolism raising questions about the dosing regimen for dalteparin in the very obese. Br J Haematol. 2008;142:487–9

    Article  PubMed  Google Scholar 

  11. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42–8

    CAS  PubMed  Google Scholar 

  12. Al-Yaseen E, Wells PS, Anderson J et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005;3:100–2

    Article  CAS  PubMed  Google Scholar 

  13. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129:407–17

    Article  CAS  PubMed  Google Scholar 

  14. Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015;68:33–47

    PubMed  PubMed Central  Google Scholar 

  15. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064–83

    Article  CAS  PubMed  Google Scholar 

  16. Meyer zu Schwabedissen C, Mevissen V, Schmitz F et al. Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol. 2006;62:713–20

    Article  CAS  PubMed  Google Scholar 

  17. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517

    Article  PubMed  Google Scholar 

  18. Upreti VV, Wang J, Barrett YC et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218–26

    Article  CAS  PubMed  Google Scholar 

  20. Morrill AM, Ge D, Willett KC. Dosing of target-specific oral anticoagulants in special populations. Ann Pharmacother. 2015;49:1031–45

    Article  CAS  PubMed  Google Scholar 

  21. Buckley LF, Rybak E, Aldemerdash A et al. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40:46–52

    Article  PubMed  Google Scholar 

  22. Di Minno MN, Lupoli R, Di Minno A et al. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials. Ann Med. 2015;47:61–88

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    Kristine Chobanyan-Jürgens &  Stefan Engeli

  2. Clinical Research Center Hannover, Medizinische Hochschule Hannover, Hannover, Deutschland

    Marcus May

Authors
  1. Kristine Chobanyan-Jürgens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Engeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcus May
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Engeli.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chobanyan-Jürgens, K., Engeli, S. & May, M. Antikoagulation des adipösen Patienten. CV 17, 38–42 (2017). https://doi.org/10.1007/s15027-017-1143-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-017-1143-8

Search

Navigation